longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Merck & Co. Inc. Stock Underperforms Monday When Compared To Competitors

MarketWatch Automated
Jul 6, 2026 at 08:33 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Merck & Co. (MRK) shares fell 2.15% to $126.78 on Monday, underperforming the broader market as the S&P 500 and Dow Jones rose. The stock closed 2.69% below its 52-week high of $130.29. Trading volume was lower than the 50-day average. Compared to competitors, Merck's decline was steeper than Johnson & Johnson and Eli Lilly but milder than Pfizer.

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Merck & Co. Inc. (MRK) shed 2.15% to $126.78 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 0.72% to 7,537.43 and the Dow Jones Industrial Average rising 0.29% to 53,055.91.

Merck & Co. Inc. closed 2.69% short of its 52-week high of $130.29, which the company reached on June 30th.

The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Johnson & Johnson (JNJ) fell 1.41% to $259.33, Pfizer Inc. (PFE) fell 2.47% to $23.72, and Eli Lilly & Co. (LLY) fell 1.14% to $1,200.06.

Trading volume (9.2 M) remained 1.4 million below its 50-day average volume of 10.6 M.

Data source: Dow Jones Market Data, FactSet. Data compiled July 6, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

07-06-26 1633ET

Login to unlock591characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Recommended Readings

  • Feb 2, 2026 at 10:32 PMReminder: Please pay close attention to the following (all times are in Beijing time)
  • Dec 19, 2025 at 08:36 PMTrump boasts of a "great victory": Nine major pharmaceutical companies reach a price reduction agreement in exchange for…
  • Oct 30, 2025 at 10:55 AMMerck's third-quarter revenue exceeded expectations, with strong sales of the COVID-19 vaccine Capvaxive
  • Jul 31, 2025 at 08:04 PM60-day countdown, Trump threatens to use "all tools" to force drug companies to lower prices, pharmaceutical stocks plum…
  • Jul 9, 2025 at 06:34 AMGlobal pharmaceutical companies under immense pressure: A "patent expiration wave" is expected in the coming years

Related Stocks

Merck

Merck

USMRK

-1.91%

Johnson & Johnson

Johnson & Johnson

USJNJ

Pfizer

Pfizer

USPFE

LongbridgeAI